Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Webcasts|June 15, 2021
Transforming Water to Meet Strict and Consistent Microbial Control While Reducing OPEX
Author(s)Evoqua
*Live: Tuesday, June 15, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST* With defined criteria for conductivity, total organic carbon, and bacteria, purified water is a critical ingredient and processing aid for many pharmaceutical companies. Learn how your facility can achieve consistent high purity quality water while reducing total maintenance and operating costs. *On Demand Until June 15, 2022*
Register free:
Event Overview:
With defined criteria for conductivity, total organic carbon, and bacteria, purified water is a critical ingredient and processing aid for many pharmaceutical companies, cosmetic manufacturers, makers of medical devices, and personal care products. Learn how your facility can achieve consistent high purity quality water while reducing total maintenance and operating costs.
Key Learning Objectives:
- Review the common challenges and opportunities with high purity and water for injection applications
- Learn about Electrodeionization technology and how it compares to traditional solutions
- Understand Electrodeionization technology and its ability to attain tight and consistent microbial control
- Review considerations when making the switch to Electrodeionization, the ROI and potential savings in maintenance and operating costs
- Hear case studies of how facilities are improving microbial control while reducing OPEX
Time and Date: Tuesday, June 15, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
Register free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.